Compare SAM & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAM | TMDX |
|---|---|---|
| Founded | 1984 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 1996 | 2019 |
| Metric | SAM | TMDX |
|---|---|---|
| Price | $164.24 | $71.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $233.70 | $148.22 |
| AVG Volume (30 Days) | 265.2K | ★ 1.9M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 95.45 | ★ 382.18 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $1,964,994,000.00 | $605,494,000.00 |
| Revenue This Year | $1.02 | $24.25 |
| Revenue Next Year | $1.31 | $18.75 |
| P/E Ratio | ★ N/A | $348.45 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $162.02 | $60.11 |
| 52 Week High | $264.46 | $156.00 |
| Indicator | SAM | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 27.27 | 42.17 |
| Support Level | N/A | $60.11 |
| Resistance Level | $228.42 | $120.60 |
| Average True Range (ATR) | 6.34 | 3.83 |
| MACD | -0.27 | 1.98 |
| Stochastic Oscillator | 8.14 | 85.37 |
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.